Phibro Animal Health (PAHC) Expected to Announce Earnings on Wednesday

Key Points

• Phibro Animal Health is expected to report fiscal Q4 2026 results after market close on August 26, with analysts forecasting earnings of $0.72 per share and revenue of approximately $381.2 million. The earnings call is scheduled for August 27.
• The company declared a quarterly dividend of $0.12 per share, payable September 23 to shareholders of record on September 2. The annualized dividend is $0.48, representing a 1.4% yield.
• Analyst sentiment is cautious: PAHC has a consensus “Hold” rating and an average price target of $42.50, while shares recently traded at $34.65. Institutional investors own 99.34% of the company’s stock.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) is anticipated to release its Q4 2026 results after the market closes on Wednesday, August 26th. Analysts expect the company to post earnings of $0.72 per share and revenue of $381.1760 million for the quarter. Interested persons may visit the the company's upcoming Q4 2026 earning overview page for the latest details on the call scheduled for Thursday, August 27, 2026 at 9:00 AM ET.

Phibro Animal Health Stock Up 0.1%

Shares of PAHC stock opened at $34.65 on Wednesday. Phibro Animal Health has a 1-year low of $28.25 and a 1-year high of $60.08. The stock's fifty day moving average price is $33.44 and its 200 day moving average price is $42.72. The company has a debt-to-equity ratio of 1.97, a current ratio of 3.17 and a quick ratio of 1.26. The company has a market cap of $1.41 billion, a price-to-earnings ratio of 14.87, a price-to-earnings-growth ratio of 0.49 and a beta of 0.46.

Phibro Animal Health Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 23rd. Shareholders of record on Wednesday, September 2nd will be issued a $0.12 dividend. This represents a $0.48 annualized dividend and a yield of 1.4%. The ex-dividend date of this dividend is Wednesday, September 2nd. Phibro Animal Health's dividend payout ratio (DPR) is currently 20.60%.

Hedge Funds Weigh In On Phibro Animal Health

A number of institutional investors have recently bought and sold shares of PAHC. Rafferty Asset Management LLC acquired a new stake in Phibro Animal Health during the 4th quarter worth about $203,000. Brooklyn Investment Group grew its holdings in Phibro Animal Health by 8.7% during the fourth quarter. Brooklyn Investment Group now owns 6,757 shares of the company's stock worth $255,000 after acquiring an additional 538 shares during the period. Creative Planning acquired a new stake in Phibro Animal Health during the third quarter worth about $217,000. Scotia Capital Inc. acquired a new stake in Phibro Animal Health during the third quarter worth about $227,000. Finally, Two Sigma Investments LP purchased a new position in Phibro Animal Health during the third quarter valued at approximately $275,000. 99.34% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

PAHC has been the topic of a number of research analyst reports. Citigroup dropped their price target on Phibro Animal Health from $62.00 to $44.00 and set a "neutral" rating on the stock in a research note on Thursday, May 14th. Weiss Ratings lowered shares of Phibro Animal Health from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Monday, June 15th. Zacks Research cut shares of Phibro Animal Health from a "strong-buy" rating to a "hold" rating in a research note on Thursday, May 21st. Finally, Wall Street Zen downgraded shares of Phibro Animal Health from a "strong-buy" rating to a "buy" rating in a research report on Saturday, May 9th. One investment analyst has rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $42.50.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation NASDAQ: PAHC is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro's portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source